MIRUM PHARMAC. DL-,0001 Aktie

Mirum expects 2026 revenue of $680–700 million and lays out a tight timeline with several potential stock catalysts, including a PDUFA date for zilurgisertib at the end of the month and Phase III readouts for brelovitug (AZURE‑1 later this month, AZURE‑4 in Q4). Other expected data: EXPAND results in Q4, VANTAGE results in Q1, and multiple filings (BLA/BLA‑/NDA/sNDA) in the first half of next year. Management highlights opportunities in underdiagnosed indications such as hepatitis delta, but also notes regulatory uncertainties for volixibat/PSC following FDA guidance; Mirum is also expanding use of AI tools such as Microsoft Copilot. » Mere på de.investing.com

Mirum Pharmaceuticals announced a growth plan focused on acquisitions, product launches and indication expansions for neglected therapies in rare diseases. The company reports three approved drugs with annualized revenues of around $680–700 million, with LIVMARLI seen as the main growth driver and a projected peak sales potential of over $1 billion. Near‑term catalysts include several phase‑III readouts (including LIVMARLI, Brelovitug and Volixibat) and a PDUFA decision for zilurgisertib; Volixibat faces a complex FDA pathway but received breakthrough designation and is heading toward an NDA submission in H1 2025. Management sees no immediate financing need, prefers acquisitions over a sale process and aims for profitability via capital‑efficient acquisitions and commercialization. » Mere på de.investing.com

Mirum Pharmaceuticals stock rose to an all-time high of 125.41 USD, bringing market capitalization to about 7.6 billion USD after a one-year gain of roughly 147%. InvestingPro rates the stock as significantly overvalued versus its fair-value estimate, despite reported revenue growth of around 50% in the last twelve months. Mirum placed convertible notes totaling 600 million USD (0.00% coupon, maturing 2032) and received several analyst price targets between 145 and 185 USD; the company also acquired zilurgisertib from Incyte for 16 million USD. » Mere på de.investing.com